PhD Scientific Days 2023
Budapest, 22-23 June 2023
Clinical Medicine I.
Association between serum GDF15 levels and all–cause mortality in heart failure patients undergoing heart transplantation
Előadó neve
Dr. Sayour, Alex Ali
Neptun code
ABR37T
Előadó munkahelye
Heart and Vascular Center, Semmelweis University, Budapest
Előadó telefonszáma
06208258126
Előadó e-mail címe
alexali.sayour@gmail.com
Az előadás címe
Association between serum GDF15 levels and all–cause mortality in heart failure patients undergoing heart transplantation
Szerző(k) neve és munkahelye
Alex Ali Sayour1, Krisztián Kovács2, Attila Oláh1, Mihály Ruppert1, Bálint András Barta1, Hanna Oberling1, Zsolt Bagyura1, Balázs Sax1, Krisztina Heltai1, Kálmán Benke1, Miklós Pólos1, István Hartyánszky1, Barna Vásárhelyi2, Béla Merkely1, Tamás Radovits1
1Heart and Vascular Center, Semmelweis University, Budapest
2Department of Laboratory Medicine, Semmelweis University, Budapest
Bemutatás módja
Szóbeli
Szekció
Clinical Medicine I.
Language of the presentation
English
Preferred session
Clinical Medicine
Összefoglaló szövege
Introduction: Circulating growth differentiation factor 15 (GDF15) predicts adverse outcomes in patients with heart failure (HF). However, clinically actionable biomarkers in patients with severe HF that predict post–orthotopic heart transplantation (HTX) outcomes are scarce. Since GDF15 is a non–cardiac–specific marker of cellular stress, it might also predict post–HTX outcomes in these patients.
Aims: To characterize association between pre–HTX serum GDF15 and post–HTX outcomes in patients with end–stage HF.
Method: Using ELISA, serum GDF15 was measured in 260 healthy controls, and 343 consecutive end–stage HF patients free of mechanical circulatory support undergoing HTX. Then, these HF patients were followed for at least 1 year after HTX. The primary outcome was the association between pre–HTX GDF15 levels in patients with HF and mortality within 1 year after HTX, assessed using Cox regression analyses.
Results: End–stage HF patients had significantly higher serum GDF15 levels (median: 2032 pg/mL, interquartile range [IQR]: 1234–3978 pg/mL) compared with healthy controls (median: 215 pg/mL, IQR: 138–338 pg/mL) (p<0.001). Patients with pre–HTX serum GDF15 higher than 2550 pg/mL had significantly greater risk of death within 1 year of HTX, compared to those with lower values (hazard ratio [HR]: 3.37, 95% confidence interval [CI]: 1.94–5.86, p<0.001), even after adjusting for age, sex, body mass index, pulmonary vascular resistance, estimated glomerular filtration rate, bilirubin, and donor ischemic time (adjusted HR: 2.82, 95% CI: 1.48–5.37, p=0.002).
Conclusion: In patients with severe HF, pre–HTX GDF15 level is an independent predictor of 1–year mortality following HTX. This could inform clinical decision–making in these patients and might highlight the relevance of pharmacological interventions that alter GDF15 levels.
Funding: Supported by the ÚNKP-22-3-II New National Excellence Program of the Ministry for Culture and Innovation from the source of the National Research, Development and Innovation Fund; NVKP_16-1–2016-0017; 2020-4.1.1.-TKP2020; K134939; TKP2021-EGA-23
University and Doctoral School
Semmelweis University, Doctoral School of Theoretical and Translational Medicine
Supervisor
Tamás Radovits, MD PhD
Publication of my abstract
I do not give consent to the publication of my abstract on the website of the congress.
Kind
Szabad
Status
elfogadva
Accepted presentation method
szóbeli
Előadás fájl jóváhagyás
nem rendelkezett róla
Előadó
4603
Start
10:15
End
10:30
Authors (legacy)
Alex Ali Sayour1, Krisztián Kovács2, Attila Oláh1, Mihály Ruppert1, Bálint András Barta1, Hanna Oberling1, Zsolt Bagyura1, Balázs Sax1, Krisztina Heltai1, Kálmán Benke1, Miklós Pólos1, István Hartyánszky1, Barna Vásárhelyi2, Béla Merkely1, Tamás Radovits1
1Heart and Vascular Center, Semmelweis University, Budapest
2Department of Laboratory Medicine, Semmelweis University, Budapest